Abstract
Exposure-response modeling facilitates effective dosing regimen selection in clinical drug development, where the end points are often disease scores and not physiological variables. Appropriate models need to be consistent with pharmacology and identifiable from the time courses of available data. This article describes a general framework of applying mechanism-based models to various types of clinical end points. Placebo and drug model parameterization, interpretation, and assessment are discussed with a focus on the indirect response models. © 2014 ASCPT All rights reserved 2163-8306/14.
Cite
CITATION STYLE
Hu, C. (2014). Exposure-response modeling of clinical end points using latent variable indirect response models. CPT: Pharmacometrics and Systems Pharmacology, 3(6). https://doi.org/10.1038/psp.2014.15
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.